|Invasive fungal infections are a serious cause of mortality in many patients including an increasing number of immunocompromised patients. Few treatment choices exist and first-line therapies have significant limitations due to safety problems and the lack of broad-spectrum activity. There is a need for novel antibacterial/antifungal agents and efficient methods of making these agents.
Researchers at Purdue University have identified several compounds with novel structures that indicate promising antibacterial and antifungal activity. Researchers evaluated the compounds against important bacterial, yeast, and mold pathogens. Preliminary results demonstrated promising activity against toxigenic strains of Clostridium difficile. The compounds did not show a side effect on beneficial intestinal microflora and were nontoxic. Researchers are currently preparing analogues of the antibacterial and antifungal lead compounds to improve potency and physicochemical properties for new therapeutic development.
-No effect on beneficial intestinal microflora
-Treatment for fungal and bacterial infections
Aug 13, 2018
Nov 27, 2018
Apr 10, 2018
Oct 2, 2018
Apr 24, 2017
Purdue Office of Technology Commercialization
The Convergence Center
101 Foundry Drive, Suite 2500
West Lafayette, IN 47906
Phone: (765) 588-3475
Fax: (765) 463-3486